Analytical characterization of ch14.18: a mouse-human chimeric disialoganglioside-specific therapeutic antibody.

Ch14.18 is a mouse-human chimeric monoclonal antibody to the disialoganglioside (GD2) glycolipid. In the clinic, this antibody has been shown to be effective in the treatment of children with high-risk neuroblastoma, either alone or in combination therapy.